⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6098670 | 1.00 | — | — | |
| SCHEMBL3184989 | 1.00 | — | — | |
| SCHEMBL1668760 | 1.00 | — | — | |
| SCHEMBL4609252 | 0.82 | GABRR1 (0.33) | — | |
| SCHEMBL2934187 | 0.82 | CHRNB2 (0.32) | — | |
| SCHEMBL17801599 | 0.82 | LOXL2 (0.33) | — | |
| SCHEMBL2934195 | 0.82 | CHRNB2 (0.32) | — | |
| SCHEMBL18957048 | 0.82 | GABRR1 (0.33) | — | |
| SCHEMBL3197102 | 0.82 | GABRR1 (0.33) | — | |
| SCHEMBL20476090 | 0.82 | LOXL2 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240166669-A1 | QUINAZOLINE AMINE DERIVATIVES AS KRAS INHIBITORS | NIKANG THERAPEUTICS, INC. | 2024-05-23 | — | — | US | disclosed |
| WO-2024091409-A1 | TRICYCLIC DERIVATIVES AS KRAS INHIBITORS | NIKANG THERAPEUTICS, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| EP-4301363-A1 | QUINAZOLINE AMINE DERIVATIVES AS KRAS INHIBITORS | Nikang Therapeutics, Inc. (US) | 2024-01-10 | — | — | EP | disclosed |
| US-20230140395-A1 | NOVEL IMIDAZOLE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND USE THEREOF | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) | 2023-05-04 | — | — | US | disclosed |
| CN-112010864-B | Vascular endothelial growth factor receptor inhibitor and preparation method and application thereof | 江苏威凯尔医药科技有限公司 | 2022-08-26 | — | — | CN | disclosed |
| EP-3746435-B1 | SUBSTITUTED QUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER (US) | 2022-08-03 | — | — | EP | disclosed |
| CN-109563043-B | Substituted pyridines as inhibitors of DNMT1 | 葛兰素史密斯克莱知识产权发展有限公司 | 2022-05-31 | — | — | CN | disclosed |
| CN-110577546-B | VEGFR inhibitor and preparation method and application thereof | 江苏威凯尔医药科技有限公司 | 2021-09-07 | — | — | CN | disclosed |
| EP-3746435-A1 | SUBSTITUTED QUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | Pfizer Inc. (US) | 2020-12-09 | — | — | EP | disclosed |
| CN-112010864-A | Vascular endothelial growth factor receptor inhibitor and preparation method and application thereof | 江苏威凯尔医药科技有限公司 | 2020-12-01 | — | — | CN | disclosed |
| EP-2217226-B1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2015-07-22 | — | — | EP | disclosed |
| US-20130045962-A1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2013-02-21 | — | — | US | disclosed |
| US-20120046300-A1 | Quinazoline Derivatives as Angiogenesis Inhibitors | HENNEQUIN LAURENT FRANCOIS ANDRE (FR) | 2012-02-23 | — | — | US | disclosed |
| US-7989460-B2 | potent kinase insert domain-containing receptor (KDR) inhibitors with improved selectivity and pharmacokinetics; VEGF (vascular endothelial growth factor) inhibitors; cancer and rheumatoid arthritis; e.g. 7-(2-[4-(acetylmethyl)piperazin-1-yl]ethoxy)-6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]quinazoline | ASTRAZENECA AB (SE) | 2011-08-02 | — | — | US | disclosed |
| EP-2217226-A1 | PEPTIDE DEFORMYLASE INHIBITORS | GlaxoSmithKline LLC (US) | 2010-08-18 | — | — | EP | disclosed |
| US-20090306066-A1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2009-12-10 | — | — | US | disclosed |
| WO-2009061879-A1 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-05-14 | — | — | WO | disclosed |
| US-20080058342-A1 | Quinazoline Derivatives As Angiogenesis Inhibitors | ASTRAZENECA AB (SE) | 2008-03-06 | — | — | US | disclosed |
| EP-1658280-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | AstraZeneca AB (SE) | 2006-05-24 | — | — | EP | disclosed |
| WO-2005014582-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2005-02-17 | — | — | WO | disclosed |